Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance
Devram Sampat Ghorpade, Lale Özcan, Ze Zheng, et al.
Nature (2018) Vol. 555, Iss. 7698, pp. 673-677
Open Access | Times Cited: 250

Showing 1-25 of 250 citing articles:

Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman, Brent A. Neuschwander‐Tetri, Mary E. Rinella, et al.
Nature Medicine (2018) Vol. 24, Iss. 7, pp. 908-922
Open Access | Times Cited: 3319
Non-alcoholic fatty liver disease
Elizabeth E. Powell, Vincent Wai‐Sun Wong, Mary E. Rinella
The Lancet (2021) Vol. 397, Iss. 10290, pp. 2212-2224
Closed Access | Times Cited: 1843
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Rohit Loomba, Scott L. Friedman, Gerald I. Shulman
Cell (2021) Vol. 184, Iss. 10, pp. 2537-2564
Open Access | Times Cited: 1250
Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease
Sebastian Steven, Katie Frenis, Matthias Oelze, et al.
Oxidative Medicine and Cellular Longevity (2019) Vol. 2019, pp. 1-26
Open Access | Times Cited: 546
NAFLD as a continuum: from obesity to metabolic syndrome and diabetes
Amélio F. Godoy‐Matos, Wellington S. Silva Júnior, Cynthia Melissa Valério
Diabetology & Metabolic Syndrome (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 478
The obese adipose tissue microenvironment in cancer development and progression
Daniela F. Quail, Andrew J. Dannenberg
Nature Reviews Endocrinology (2018) Vol. 15, Iss. 3, pp. 139-154
Open Access | Times Cited: 442
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Mengwei Li, Xiaowei Chi, Ying Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 405
Coronavirus Infections and Type 2 Diabetes—Shared Pathways with Therapeutic Implications
Daniel J. Drucker
Endocrine Reviews (2020) Vol. 41, Iss. 3
Open Access | Times Cited: 391
Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
Gopanandan Parthasarathy, Xavier S. Revelo, Harmeet Malhi
Hepatology Communications (2020) Vol. 4, Iss. 4, pp. 478-492
Open Access | Times Cited: 347
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Carolyn F. Deacon
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 329
Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease
Lili Niu, Philipp E. Geyer, Nicolai J. Wewer Albrechtsen, et al.
Molecular Systems Biology (2019) Vol. 15, Iss. 3
Open Access | Times Cited: 234
Bone Marrow Mesenchymal Stem Cells-Derived Exosomal MiR-29b-3p Regulates Aging-Associated Insulin Resistance
Tian Su, Yuzhong Xiao, Ye Xiao, et al.
ACS Nano (2019)
Closed Access | Times Cited: 198
Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions
Shiying Shao, Qinqin Xu, Xuefeng Yu, et al.
Pharmacology & Therapeutics (2020) Vol. 209, pp. 107503-107503
Open Access | Times Cited: 174
Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis
Xiaobo Wang, Bishuang Cai, Xiaoming Yang, et al.
Cell Metabolism (2020) Vol. 31, Iss. 5, pp. 969-986.e7
Open Access | Times Cited: 159
Association between SII and hepatic steatosis and liver fibrosis: A population-based study
Ruijie Xie, Mengde Xiao, Lihong Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 149
COVID‐19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?
Margaret F. Bassendine, Simon H. Bridge, Geoffrey W. McCaughan, et al.
Journal of Diabetes (2020) Vol. 12, Iss. 9, pp. 649-658
Open Access | Times Cited: 145
Adipokines, Hepatokines and Myokines: Focus on Their Role and Molecular Mechanisms in Adipose Tissue Inflammation
Yakun Ren, Hao Zhao, Chunyan Yin, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 114
Inter-organ crosstalk during development and progression of type 2 diabetes mellitus
Georgia Xourafa, Melis Korbmacher, Michael Roden
Nature Reviews Endocrinology (2023) Vol. 20, Iss. 1, pp. 27-49
Open Access | Times Cited: 91
Nonalcoholic Fatty Liver Disease: A Challenge from Mechanisms to Therapy
Giovanni Tarantino, Vincenzo Citro, Domênico Capone
Journal of Clinical Medicine (2019) Vol. 9, Iss. 1, pp. 15-15
Open Access | Times Cited: 125
Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition
Elodie M. Varin, Erin E. Mulvihill, Jacqueline L. Beaudry, et al.
Cell Metabolism (2018) Vol. 29, Iss. 2, pp. 320-334.e5
Open Access | Times Cited: 119
Myeloid cell–synthesized coagulation factor X dampens antitumor immunity
Claudine Graf, Petra Wilgenbus, Sven Pagel, et al.
Science Immunology (2019) Vol. 4, Iss. 39
Open Access | Times Cited: 109
Role of Caveolin-1 in Diabetes and Its Complications
Dania Haddad, Ashraf Al Madhoun, Rasheeba Nizam, et al.
Oxidative Medicine and Cellular Longevity (2020) Vol. 2020, pp. 1-20
Open Access | Times Cited: 99
The Unique Metabolic Characteristics of Bone Marrow Adipose Tissue
Yujue Li, Yang Meng, Xijie Yu
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 89
Diabetes and COVID-19: The past, the present, and the future
Raymond Pranata, Joshua Henrina, Wilson Matthew Raffaello, et al.
Metabolism (2021) Vol. 121, pp. 154814-154814
Open Access | Times Cited: 86
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase‐4 in patients with type 2 diabetes and non‐alcoholic fatty liver disease
Yoshimasa Aso, Kanako Kato, Shintaro Sakurai, et al.
International Journal of Clinical Practice (2019) Vol. 73, Iss. 5, pp. e13335-e13335
Open Access | Times Cited: 80
Page 1 - Next Page

Scroll to top